Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)) (Q35981902)

11 August 2017

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)) (English)

1 reference

11 August 2017

1 reference

Marsoni S

1

1 reference

11 August 2017

Torri V

2

1 reference

11 August 2017

Valsecchi MG

3

1 reference

11 August 2017

Belloni C

4

1 reference

11 August 2017

Bianchi U

5

1 reference

11 August 2017

Bolis G

6

1 reference

11 August 2017

Bonazzi C

7

1 reference

11 August 2017

Colombo N

8

1 reference

11 August 2017

Epis A

9

1 reference

11 August 2017

Favalli G

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 September 1990

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

62

1 reference

11 August 2017

3

1 reference

11 August 2017

444-450

1 reference

Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

2 October 2017

Treating ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Common epithelial cancer of the ovary (2).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971438

Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study

24 September 2018

1 reference

12 December 2020

Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum

1 reference

12 December 2020

Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma

1 reference

12 December 2020

A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma

1 reference

12 December 2020

cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma

1 reference

12 December 2020

Ovarian carcinoma: a multivariate analysis of prognostic factors

1 reference

12 December 2020

Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial

1 reference

12 December 2020

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

12 December 2020

Prognostic factors in advanced ovarian carcinoma

1 reference

12 December 2020

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer

1 reference

12 December 2020

Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment

1 reference

12 December 2020

Accrual to Clinical Trials1

1 reference

12 December 2020

Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1990.315

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

2119684

1 reference